Lisinopril Capsules

Lisinopril is a synthetic peptide derivative and an oral long-acting angiotensin converting enzyme inhibitor. It reduces the concentration of angiotensin II (a strong vasoconstrictor) and aldosterone, leading to peripheral vasodilation and reduced vascular resistance, thereby lowering blood pressure. Research data show that the effect of long-term use of this product will not weaken, and there will be no blood pressure rebound after immediate discontinuation of the drug. In patients with congestive heart failure, lisinopril reduces the preload and afterload of the heart by dilating arteries and veins, increases cardiac output, and does not cause reflex tachycardia. This product rarely produces hypokalemia and hyperuricemia caused by thiazide drugs.

Chemical name of this product: 1-[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysinyl]-L-proline dihydrate.

This product is a capsule, and the contents are white or off-white granules or powder.

This product is suitable for the treatment of essential hypertension and renovascular hypertension. It can be used alone or in combination with other antihypertensive drugs such as diuretics. Patients with congestive heart failure can use this product when digitalis or diuretics are ineffective.

1 The initial dose for lowering blood pressure is usually 10 mg/time, the maintenance dose is 10 mg/time, and the maximum dose is 80 mg/time. Patients who are taking diuretics should stop taking diuretics 3 days before starting treatment with this product. For those who cannot stop taking diuretics, the initial dose is reduced to 5 mg, and then adjusted according to blood pressure. Diuretics can be used again if necessary. For patients with renal failure and creatinine clearance of 10-30 mL/min, the initial dose is 2.5 mg-5 mg/day; for patients with creatinine clearance less than 10 mL/min, the initial dose is 2.5 mg/day, and the maximum dose is 40 mg/day. 2 The initial dose for patients with chronic heart failure and hypertension is 2.5 mg/day, and the commonly used effective dose is 5 mg-20 mg, once a day. For patients with symptomatic hypotension, with or without hyponatremia, with reduced blood volume or receiving strong diuretics, they should be corrected as much as possible before using this product, and the effect of each medication on blood pressure should be carefully monitored. 3. For acute myocardial infarction, the first dose is 5 mg orally, followed by 5 mg and 10 mg after 24 hours and 48 hours respectively, followed by 10 mg per day, which should be continued for 6 weeks. Patients with low systolic blood pressure (systolic blood pressure ￡120 mmHg) or patients within 3 days after infarction should be given a lower dose of 2.5 mg. If hypotension occurs (systolic blood pressure below 100 mmHg), the maintenance dose can be temporarily reduced to 2.5 mg; if hypotension persists (systolic blood pressure below 90 mmHg for 31 hours), the drug should be discontinued. This drug can be used as a secondary prevention drug for myocardial infarction.

Controlled clinical trials have shown that this product is generally well tolerated. In most cases, adverse reactions are mild and transient in nature. In controlled clinical trials, the most common adverse reactions exhibited by this product are: dizziness (6.5%), headache (5.4%), diarrhea (3.8%) and fatigue (2.9%). Other adverse reactions with an incidence rate higher than 1% are cough, nausea, rash, symptomatic hypotension, postural hypotension, palpitations, chest pain and asthma. The most common reasons for discontinuation are headache and cough. Rare adverse reactions include: syncope, peripheral edema, dermatitis, constipation, gastritis, anxiety, insomnia, paresthesia, arthralgia, myalgia, asthma, etc. Allergic/angioneurotic edema of the face, limbs, lips, tongue, glottis and/or throat, neurogenic edema is rare (see Precautions), if it occurs, the drug should be discontinued immediately.

This product is contraindicated in patients who are allergic to any component of this product, patients with a history of angioedema caused by the use of ACE inhibitors, and patients with hyperkalemia.

Precautions for children: The dosage for children has not been determined and the research is insufficient. In newborns and infants, there is a risk of oliguria and neurological abnormalities, which may be related to the renal and cerebral ischemia caused by the product lowering blood pressure. Precautions for pregnancy and lactation: Pregnant women taking angiotensin-converting enzyme inhibitors can cause fetal and neonatal death. Once pregnancy is discovered, this product should be discontinued immediately. The use of angiotensin-converting enzyme inhibitors during pregnancy for 6-9 months can cause hypotension, skeletal dysplasia in newborns, anuria, reversible or irreversible renal failure, and even death. It is not known whether this product is secreted in human breast milk. Precautions for the elderly: Age has no effect on the efficacy and safety of this drug. However, for the elderly with renal function decline, the dosage of this drug should be reduced, and then adjusted according to blood pressure.

1. Combined use with diuretics When patients receiving this product are treated with diuretics, the antihypertensive effect is usually enhanced. For patients who have been treated with diuretics, especially those who have been treated with diuretics recently, excessive reduction in blood pressure may occur when this product is added. The possibility of symptomatic hypotension can be greatly reduced by stopping diuretics before starting treatment with this product. This product starts with a small dose and gradually adjusts the dose. 2. The antihypertensive effect is enhanced when used with other antihypertensive drugs, among which it has a greater additive effect with drugs that cause renin release or affect sympathetic activity, and a less than additive effect with beta blockers. 3. When used with potassium-retaining diuretics such as spironolactone, triamterene, and amiloride, it may cause hyperkalemia. 4. Nonsteroidal anti-inflammatory analgesics, especially indomethacin, can inhibit prostaglandin synthesis and cause water and sodium retention. When used with this product, the antihypertensive effect of this product may be weakened.

Keep in a light-proof and airtight container.

Calculated as C21H31N305 10mg

18 months

Weihai Noda Pharmaceutical Group Co., Ltd.

• Founded in:

  2004-03-03

• Address:

  No. 7, Huoju 4th Street, Weihai High-tech Industrial Development Zone

• Tax NO.:

  91371000264195518F

• Registered Funds:

  50 million yuan

• Email:

  Log in to view